Jonathan Adelson, MD
Rheumatology · Greenbelt, MDNPI 1700864501
Payments from drug & device makers
Across 260 payments — averaging $20.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$939
- Johnson & Johnson$854
- AbbVie$651
- GSK$340
- Pfizer$332
- E.r. Squibb & Sons, L.L.C.$259
- plus $2K from 28 others
What the payments were for
- Consulting fees$1753%
- Food & beverage$5,07993%
- Education$1793%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 41 | $939 |
| Johnson & Johnson(2 entities) | 29 | $854 |
| AbbVie | 32 | $651 |
| GSK | 15 | $340 |
| Pfizer | 23 | $332 |
| E.r. Squibb & Sons, L.L.C. | 15 | $259 |
| UCB, Inc. | 15 | $258 |
| Novartis | 14 | $252 |
| AstraZeneca(2 entities) | 13 | $250 |
| Mallinckrodt Hospital Products Inc. | 7 | $192 |
| Novo Nordisk | 6 | $129 |
| Aurinia Pharma U.S., Inc. | 4 | $85 |
| Sanofi | 4 | $84 |
| ANI Pharmaceuticals, Inc. | 3 | $83 |
| Pacira Pharmaceuticals Incorporated | 4 | $77 |
| Sandoz | 2 | $72 |
| Mallinckrodt Enterprises LLC | 2 | $57 |
| Hikma Pharmaceuticals USA | 3 | $49 |
| Sobi, Inc | 3 | $48 |
| Radius Health, Inc. | 2 | $48 |
| Genentech USA, Inc. | 3 | $42 |
| Merck | 3 | $42 |
| Lilly USA, LLC | 3 | $42 |
| Scilex Pharmaceuticals Inc. | 2 | $41 |
| Invivyd Inc | 2 | $38 |
| Pacira Therapeutics, Inc. | 2 | $29 |
| Saluda Medical Americas, Inc. | 1 | $24 |
| Zimmer Biomet | 1 | $21 |
| Fresenius Kabi USA, LLC | 1 | $20 |
| Sanofi Pasteur Inc. | 1 | $18 |
| Tonix Medicines, Inc. | 1 | $17 |
| Bristol Myers Squibb | 1 | $17 |
| Assertio Therapeutics, Inc. | 1 | $13 |
| Regeneron Healthcare Solutions, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- STELARA$175
- SIMPONI ARIA$175
- KRYSTEXXA$145
- Rinvoq$121
How this compares
$5,433 in reported general payments places this provider in the 55th percentile of 173 rheumatology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RybelsusSemaglutide | 31 | $35,597 |
| MounjaroTirzepatide | 11 | $11,111 |
| Colchicine | 62 | $8,266 |
| Hydroxychloroquine Sulfate | 242 | $6,444 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 180 | $4,566 |
| Lidocaine | 18 | $3,870 |
| MethotrexateMethotrexate Sodium | 150 | $3,556 |
| Potassium Chloride | 84 | $3,541 |
| Duloxetine Hcl | 125 | $3,457 |
| Gabapentin | 230 | $2,909 |
| Methylprednisolone | 120 | $2,310 |
| Cyclobenzaprine Hcl | 70 | $2,200 |
| Diclofenac Sodium | 21 | $1,995 |
| Leflunomide | 36 | $1,923 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 86 | $1,714 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskRybelsus | $129 | $35,59731 claims |
| Lilly USA, LLCMounjaro | $42 | $11,11111 claims |
| Scilex Pharmaceuticals Inc.Colchicine | $41 | $8,26662 claims |
| AbbVieSynthroid | $651 | $97520 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 173 rheumatology providers in Maryland.
Other rheumatology in Greenbelt
- Donald ThomasGreenbelt$471K
- Steven KleinHagerstown$3.4M
- Herbert BarafWheaton$1.4M
- Paul DemarcoWheaton$1.4M
- Thomas Grader BeckBaltimore$1.2M
- Michelle PetriBaltimore$1.1M
- Laura HummersBaltimore$1M
- Alan MatsumotoWheaton$720K
- Evan SiegelRockville$624K
- Jeffrey PotterWheaton$477K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.